fbpx Yourgene Health plc - Home
004-news.jpg
002-news.jpg
001-news.jpg
003-news.jpg
DSC00185r.jpg
previous arrow
next arrow

In recent years, fertility treatments and the fact women are having babies later has made multiple births more common. In 2016, around 12,000 sets of twins and about 190 sets of triplets or more were born in the UK. That means about 1 in every 65 births in the UK today are twins, triplets or more.1 Extensive studies have been carried out for cell-free DNA (cfDNA) testing in singleton pregnancies with sample numbers into the hundreds of thousands of women. In contrast, data in twin pregnancies are much scarcer, with only 11 studies previously published.2

Recently, Yourgene Health collaborated with 6 centres across the UK to conduct a prospective study, published in the American Journal of Obstetrics and Gynaecology , involving more than 1,000 women with twin pregnancies. The study has shown the Non-Invasive Prenatal Testing (NIPT), namely the IONA® test, to be effective and safe in detecting Down’s syndrome and therefore recommends that NIPT, such as the IONA® test, should be the primary test offered for Down’s syndrome (trisomy 21) screening in twins. 2 As a result, this study is of great significance as there is potential for NIPT to be useful in twin pregnancies, thereby reducing the need for invasive testing which carries the risk of losing one or more fetus. Non-invasive prenatal testing (NIPT) is a screening test used to detect the risk that a fetus will be born with certain genetic conditions. It can be performed as early as 10 weeks in pregnancy and only requires a blood sample from the mother.

Other key significant conclusions, we were able to derive from the study include:

The IONA® test shows a detection rate of >99.99% for Trisomy 21

The incidence of trisomy 21 is higher in twin than singleton pregnancies, furthermore first trimester combined screening (FTCT) in twin pregnancies has a lower detection rate (DR) (75%) and higher false positive rate (FPR) (7%) than singleton pregnancies3,4.  This study confirms that NIPT using cfDNA is the most accurate screening test for trisomy 21 in twin pregnancies (>99.99%), with screening performance similar to single pregnancies and a very low failure rates of just 0.31%. As expected, it was concluded that the predictive accuracy for trisomies 18 and 13 may be less due to biological factors.  

The IONA® test gives a valid result even with low fetal fraction 

The mean fetal fraction in the study was 12.2% (range, 3%-36%); of which 9 samples with 3% fetal fraction also provided a valid result indicating that the IONA® test is valid for even low fetal fractions. Fetal fraction is the term given to the proportion of cfDNA belonging to the placenta found in the mother’s blood. Factors known to be associated with a lower fetal fraction in singleton pregnancies include in vitro fertilization (IVF) conception and higher maternal weight, two factors that are more common in twin than singleton pregnancies.

The study was carried out at six fetal medicine  centres across the UK, with lead author, Professor Asma Khalil who is based at St George’s University Hospitals NHS Foundation Trust. St George’s University Hospitals NHS Foundation Trust is the largest healthcare provider, major teaching hospital and tertiary centre for south west London, Surrey and beyond – serving a population of 3.5 million. The other centres involved were: Leicester Royal Infirmary; the Central Manchester University Hospitals NHS Foundation Trust; Norfolk and Norwich University Hospitals NHS Foundation Trust; Leeds General Infirmary, and John Radcliffe Hospital in Oxford, United Kingdom. This follows on from a long-standing clinical relationship with these six key fetal medicine centres that were involved with the original IONA test clinical publication in 2015. 5 It is testament to the high quality and reliable performance of the IONA® test that the majority of these fetal medicine centres are using it for their NIPT offering to their high-risk patients.

Victoria Hutchinson, Clinical Lead at Yourgene states: “The partnership between Yourgene Health and the six NHS hospitals that took part in the study worked really well. The research teams were hardworking, passionate and dedicated to the study and has led to a great piece of research. They were a joy to work with and we look forward to the opportunity to collaborate again in the future. “

To read the full publication, please click here.

The IONA® test is available as clinical service, with samples analysed at Yourgene Health’s state of the art genomics laboratory in Manchester, UK with results available in 2-5 days. In addition, the IONA® test is a complete CE-IVD product for labs wishing to offer their own in-house non-invasive prenatal testing (NIPT) service. Please email This email address is being protected from spambots. You need JavaScript enabled to view it. to find out more about either of these options.

Participants in the study were recruited before the COVID-19 outbreak started, while the analysis of data and writing of the paper was carried out during the pandemic.

References

  1. https://www.nhs.uk/pregnancy/finding-out/pregnant-with-twins/#:~:text=In%20recent%20years%2C%20fertility%20treatments,are%20twins%2C%20triplets%20or%20more.
  2. AJOG. 2021 January 15. Doi: 10.1016/j.ajog.2021.01.005. Noninvasive prenatal screening in twin pregnancies with cell-free DNA using the IONA® test: a prospective multicenter study. Khalil A, Archer R, Hutchinson V, Mousa H. A, Johnstone E. D, Cameron M. J, Cohen K.E, DPhil C.I, Kelly B, Reed K, Hulme R . & Papageorghiou A. T.
  3. Mutton D, Alberman E, Hook EB. Cytogenetic and epidemiological findings in Down syndrome,England and Wales 1989 to 1993. National Down syndrome Cytogenetic Register and theAssociation of Clinical Cytogeneticists. J MedGenet 1996;33:387–94.
  4. Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasoundand maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG 2003;110:276–80.
  5. Ultrasound Obstet Gynecol. 2015 Oct 23. DOI: 10.1002/uog.15791. Clinical evaluation of the IONA® test: a non-invasive prenatal screening test for Trisomy 21, 18 and 13. Papageorghiou A, Khalil A, Forman M, Hulme R, Mazey R, Mousa HA, Johnstone ED, McKelvey A, Cohen KE, Risley M, Denman W & Kelly B.
  • New Year, New Regulations - 19 January 2022 +

    The ‘New Year's resolution’ is a tradition almost all of us are familiar with, in which a person resolves to accomplish a personal goal, continue good habits or change undesirable ones all with the intention of self-improvement. A study of over 800 million activity data points on the exercise platform Strava found that today, January 19th, is the most common day for a New Year’s resolution to be abandoned ( 1 ). If you are reading this

    Read More
  • Behind the scenes: Adapting diagnostic services during a pandemic - 11 November 2021 +

    The diagnostic testing business has always been dynamic and opportunistic , but nothing could have stretched the definition of these 2 words like a pandemic.

    Since the launch of Yourgene Genomic Services 6 months into this global pandemic – born from a legacy, well established NIPT service laboratory, a modest acquisition, and an unprecedented national genomic testing demand, we have vastly expanded our testing capacity by converting every spare inch of underutilised office space created by remote

    Read More
  • Overprescribing within the NHS - 02 November 2021 +

    “Good for you, good for us but is it good for everybody?”
    Overprescribing within the NHS – October 2021


    The NHS is currently the 5th largest global employer; with over 1.3m employees and receiving around 10% of the UK Government’s annual spending. It is estimated that the NHS deals with 336 million ‘patient visits’ per year, - many of whom will receive some form of at least one ‘prescription’ per visit and at a current charge in

    Read More
  • The role genomics plays in relationships - 18 August 2021 +

    According to National Today, the website dedicated to highlighting every day celebrations and holidays, August 18 th is ‘National Couple’s Day’ – a day to celebrate the important relationships in life. Whilst not an official holiday or observance in any country, the clinical team at Yourgene Health wanted to use this opportunity to reflect upon the pivotal role that genomics plays in relationships across the world.

    Earlier this year a study, published in Nature Human Behaviour,

    Read More
  • NIPT for Sex Chromosome Aneuploidies and Autosomal Aneuploidies. A Q&A with Dr Greg Fitzgibbon - 26 May 2021 +

    Yourgene Health has recently launched IONA ® Care , an advanced prenatal screening test that performs whole-genome analysis to measure the likelihood that a pregnant woman is carrying a fetus with one the most common trisomies (trisomy 21, 18 and 13), any other Autosomal Aneuploidy (AA) or a Sex Chromosome Aneuploidy (SCA). IONA ® Care is available from the Yourgene Genomic Services laboratory in Manchester, UK. The test is available as a menu, enabling pregnant women, their families

    Read More
  • COVID-19 testing and the need for regulation - 6 May 2021 +

    The COVID-19 pandemic presented huge challenges worldwide. In response to the unprecedented need for COVID-19 PCR testing, the UK government set up a new network of Lighthouse laboratories across the country to provide the required capacity for testing thousands of samples each day. These laboratories proved a vital part of the test and trace strategy but were also under immense pressure to meet their targets and, following an investigation by Panorama , it was found that

    Read More
  • Yourgene on World Creativity and Innovation Day 2021 - 21 April 2021 +

    Innovation and creativity are two pillars at the heart of technological and scientific advances. The instrumental role they play has been recognised by the United Nations (UNN), who have designated a special day to raise awareness of the importance of innovation in culture and economic growth worldwide: 21st April. World Creativity and Innovation Day (UNN) is a day to encourage people to “think outside the box”, find new perspectives which push personal growth, identify different

    Read More
  • The IONA® test recommended for twin pregnancies screening for Down’s syndrome - 7 April 2021 +

    In recent years, fertility treatments and the fact women are having babies later has made multiple births more common. In 2016, around 12,000 sets of twins and about 190 sets of triplets or more were born in the UK. That means about 1 in every 65 births in the UK today are twins, triplets or more. 1 Extensive studies have been carried out for cell-free DNA (cfDNA) testing in singleton pregnancies with sample numbers into

    Read More
  • Blood clots, inherited thrombophilia and COVID-19 - 25 March 2021 +

    Recent reports in the media from a collection of European countries suggest that there may be cause for concern with regards to the Oxford AstraZeneca COVID-19 vaccine and abnormal blood clotting. According to Norway’s medicines agency (NoMA), four new cases of “serious blood clotting in adults” have been identified following a recent review (1). Austria have suspended the use of one particular batch of the vaccine after two events, including an individual diagnosed with multiple

    Read More
  • COVID-19 strains - what are they and why do they matter? A Q&A with Dr Michael Risley - 28 January 2021 +

    The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the beginning of the global COVID-19 outbreak, the diagnostic and research community has undertaken an unprecedented effort to understand how best to manage, eradicate and prevent the disease. In recent months we have seen the rollout of ambitious vaccination schedules worldwide, as well as the strengthening of

    Read More
  • So much to be proud of! - 23 December 2020 +

    As many have already said and written, this year has been like none other. This has been especially true for conferences and exhibitions. Every year, the commercial team at Yourgene look forward to exhibiting at various conferences globally. It’s a chance to meet our partners and customers, as well as form new relationships. With the COVID-19 pandemic none of this was possible, so when we heard that the Taiwan Healthcare Expo was still going ahead,

    Read More
  • COVID-19 vaccines and the continued role of testing - 16 November 2020 +

    Last week we had the great news that a safe and effective vaccine against SARS-CoV-2 should soon be available. Thanks to the work of Pfizer and  BioNTech , we may have the opportunity to start vaccinating those at highest risk of severe disease towards the end of this year  and into 2021.  The interim analysis of their clinical trial has indicated that it is more than 90% effective in preventing COVID - 19 in participants who haven’t

    Read More
  • The role of DPYD testing in managing a successful response to the COVID-19 pandemic - 5 November 2020 +

    Since the beginning of the global COVID-19 outbreak, the diagnostic and research community has undertaken an unprecedented effort to understand how best to manage, eradicate and prevent the disease. Two key pillars in the fight against the pandemic are establishing a robust testing strategy and implementing procedures and processes to reduce the burden on healthcare systems.  

    Independent SAGE recently published a document containing core recommendations for how best to optimize and develop the current testing

    Read More
  • 1